Fedratinib Medicine 12 June 2018 Extended indication Myelofibrosis Therapeutic value No judgement Total cost Registration phase Clinical trials Product Active substance Fedratinib Domain Oncology and Hematology Reason of inclusion Main indication Other hematology Extended indication Myelofibrosis Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Celgene Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Capsule Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks JAK2 inhibitor Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity New medicine ATMP Unknown Submission date Expected Registration January 2020 Orphan drug Unknown Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks In 2013 zijn de klinische studies door Sanofi stopgezet wegens ernstige bijwerkingen (Wernicke’s encephalopathie). Celgene heeft Federatinib nu opgekocht. Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times a day Dosage per administration 400 mg References NCT01437787 Additional remarks Expected patient volume per year Patient volume 20 - 143 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR Additional remarks 143 diagnoses in 2016. De inschatting van de werkgroep is 20 patiënten. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Polycythemia Vera References Fabrikant Additional remarks Other information Additional remarks